The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Could CSF1R expression findings from MONSTAR-SCREEN-2 be used to guide treatment decisions?
Kyosuke Seguchi, MD, Kameda Medical Center, Kamogawa, Japan, discusses how results from the MONSTAR-SCREEN-2 do not at this stage support using CSF1R expression to guide treatment decisions for patients with gastric cancer, but instead as a candidate prognostic biomarker. In exploratory analysis of microsatellite-stable cancer in patients treated with immune checkpoint inhibitors, progression-free survival did not differ by CSF1R expression. Dr Seguchi highlights that the immediate clinical value of CSF1R could be in risk-stratification and trial design, with CSF1R able to identify a subset of patients with immunosuppressive, advanced gastric cancer. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
